A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/combo-therapy-boosts-early-cml-response-not-long-term-2026a1000f6z?src=rss
Author :
Publish date : 2026-05-12 03:14:00
Copyright for syndicated content belongs to the linked Source.
